NCT02973763View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

February 4, 2021

Study Completion Date

August 1, 2023

Conditions
NSCLC
Interventions
DRUG

Alflutinib

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT02973763 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter